UPDATE: Citigroup Reiterates Buy Rating, Raises PT on Dr. Reddy's Laboratories After Disappointing 3Q
Posted on February 15, 2013 at 10:05 AM EST
In a report published Friday, Citigroup reiterated its Buy rating on Dr. Reddy's Laboratories (NYSE: RDY ), and raised its price target to $39.36. Citigroup noted, “We rate DRL Buy with a Target Price of $39.36. REDY, in our view, is among the best placed to capitalize on the multiple